Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy. - Wikidata - wikimedia - TriplyDB

Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.

Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.

http://www.wikidata.org/entity/Q35127299

about

Pseudomonas aeruginosa urinary tract infections in hospitalized patients: Mortality and prognostic factors.Carbapenem-resistant Pseudomonas aeruginosa: association with virulence genes and biofilm formation Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study Modification of the susceptibility of gram-negative rods producing ESβLS to β-lactams by the efflux phenomenon.Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis Innate Immune Signaling Activated by MDR Bacteria in the Airway Bloodstream infections in acute myeloid leukemia patients treated according to the Finnish Leukemia Group AML-2003 protocol - a prospective nationwide study.Multidrug-resistant bacteria in hematology patients: emerging threats.Burden of antimicrobial resistance in an era of decreasing susceptibility.Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection.Pseudomonas aeruginosa infection liberates transmissible, cytotoxic prion amyloids.WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa.Enhancement of photo-bactericidal effect of tetrasulfonated hydroxyaluminum phthalocyanine on Pseudomonas aeruginosa.Comparison of mono- and combination antibiotic therapy for the treatment of Pseudomonas aeruginosa bacteraemia: A cumulative meta-analysis of cohort studies.

P2860

Q33732032-FFE4C1A3-4B05-4625-ACC7-1A4BA02D80DA Q33796573-4AE6BC53-AFA3-42BA-883A-36B66DF6460D Q33867208-D35C16CE-C73E-4A55-A1C5-22735928CF74 Q35203279-A608F71E-56D3-40E3-AC69-601155F3AED4 Q35673458-9C1BBACD-6269-4BF5-AC1B-2C86B71420C9 Q36422470-03AAF5D8-1215-4715-B9C0-57EB774F2F9E Q38690746-0B7C4A2F-919D-4827-95E8-9BF670812AF2 Q38838498-A16B5E43-5EEF-4BF8-8984-CC97324874D2 Q39350575-F6E15411-638B-42D1-85A9-103E034FAF1B Q40245763-744FE2DB-7382-4B3F-93A3-59E476B94E34 Q40289742-403A0D3D-4EF4-452A-A651-3E40EDF4437C Q40296000-8FDA3775-031D-44AF-B17B-8253B2EA9FAC Q42276294-50380C64-D5FF-4897-861C-77A52225CB55 Q47593426-7961C4E5-0FA4-4B36-A13F-1D1C3BE87789 Q49884441-75C8064A-D183-44A4-B7BB-5BC88D13A4A3

P2860

Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.

http://www.wikidata.org/entity/Q35127299

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Risk factors for mortality in ...... ination antimicrobial therapy.

@ast

Risk factors for mortality in ...... ination antimicrobial therapy.

@en

type

label

Risk factors for mortality in ...... ination antimicrobial therapy.

@ast

Risk factors for mortality in ...... ination antimicrobial therapy.

@en

prefLabel

Risk factors for mortality in ...... ination antimicrobial therapy.

@ast

Risk factors for mortality in ...... ination antimicrobial therapy.

@en

P1433

Q35127299-66050F6D-EFDD-42A4-B629-771B9F0D6E0B

P1476

Q35127299-B99C6A6E-47DB-4C71-B232-13FA87F00C22

P2093

Q35127299-05F3D6F0-8A4A-4931-9A6E-D96679C7A100

Q35127299-19506CF1-8BC5-4BE4-9D46-1A986C409E12

Q35127299-26E4CF61-C945-4A53-8298-C86D79A28A1E

Q35127299-35334828-4FAE-4D8B-B5A1-CBE88D4DF537

Q35127299-4A552672-80DE-4444-A531-61C4C0A6CE8D

Q35127299-C3A305C6-49CB-45DF-B400-1149338F52FC

Q35127299-EF5CDE52-9CA8-4212-BDAC-B35E2C1860FF

P2860

Q35127299-11AF870E-DB9A-4542-AD18-ECCF78526C63

Q35127299-1C794D89-0441-4D44-A387-EA9A7E69D00C

Q35127299-2429A4FE-4646-4395-85F2-B8F9A15B42CA

Q35127299-26B254BA-9F40-4B78-9556-49A84D3963FF

Q35127299-29DFE80E-6DDF-4336-BBC9-8C14DEF10879

Q35127299-45CFB5C1-58FE-4FB6-8BD6-59BF2184CF1B

Q35127299-49E499FC-416E-49C1-8B37-019777745FBC

Q35127299-7A05FAE7-1AB1-4932-B88E-0731F3C9807D

Q35127299-7C485385-2F68-4E37-8A80-EE6EB7A60D7C

Q35127299-88583F9C-FE62-4D3D-B2AE-27ABF3210093

P2888

Q35127299-01A73D86-2CCB-4DC4-A878-2800DA1236BF

P304

Q35127299-F65A4142-2441-4D34-ADD1-E26D72A48293

P31

Q35127299-C5A43FEB-6E43-4D01-A4B2-C186C0727820

P356

Q35127299-48BC2D42-9E45-435E-8D7B-BCFDF52FC64C

P478

Q35127299-112E4A92-25BC-4559-A95E-0E603385BA2D

P577

Q35127299-3B22AE57-2672-40D5-AE72-F2BE83B43F42

P5875

Q35127299-047DE354-A094-4BC5-9362-219E9B2967C5

P6179

Q35127299-B7A29678-5C57-46DF-9576-20C7BB25DDC5

P698

Q35127299-22ADE31B-8CA3-4F3C-BC8F-CD500E9596AC

P932

Q35127299-19C372C6-C2DD-4FE0-818E-58ECE4399BDC

P356

1471-2334-14-161

P1433

BMC Infectious Diseases

P1476

Risk factors for mortality in ...... ination antimicrobial therapy.

@en

P2093

Ji Young Kang

http://www.w3.org/2001/XMLSchema#string

Kang Gyun Park

http://www.w3.org/2001/XMLSchema#string

Sang Il Kim

http://www.w3.org/2001/XMLSchema#string

Yang Ree Kim

http://www.w3.org/2001/XMLSchema#string

Yeon Joon Park

http://www.w3.org/2001/XMLSchema#string

Yoon Hee Jun

http://www.w3.org/2001/XMLSchema#string

Youn Jeong Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis.

Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study.

Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009

Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.

Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.

Pseudomonas aeruginosa bloodstream infections: how should we treat them?

Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy?

P2888

1471-2334-14-161

P304

161

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2334-14-161

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261031992

http://www.w3.org/2001/XMLSchema#string

P6179

1036763236

http://www.w3.org/2001/XMLSchema#string

P698

24655422

http://www.w3.org/2001/XMLSchema#string

P932

3994322

http://www.w3.org/2001/XMLSchema#string